Please login to the form below

Not currently logged in
Email:
Password:

rosiglitazone

This page shows the latest rosiglitazone news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

In 2010 GlaxoSmithKline went down the same path with its Avandia (rosiglitazone) product, although its failed trial used a different biomarker to determine risk based on cerebrospinal fluid sampling.

Latest news

  • AZ's Onglyza may increase mortality, says FDA AZ's Onglyza may increase mortality, says FDA

    The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market - as well as the imposition of prescribing restrictions in the US -

  • GSK to hire doctors as product champions GSK to hire doctors as product champions

    and Wellbutrin (bupropion) and a failure to report safety data for diabetes drug Avandia (rosiglitazone).

  • Use data responsibly Use data responsibly

    For example, an aggregate analysis of reports of acute myocardial infarction (AMI) in rosiglitazone randomised clinical trials (RCTs) excluded those RCTs that had no reports of AMI (ie those that demonstrated ... a positive result) and found a

  • FDA to review safety of AZ's saxagliptin FDA to review safety of AZ's saxagliptin

    studies. The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market and restriction in the US on concerns of cardiovascular toxicity.

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    The drug marks GSK's return to the massive diabetes market following severe restrictions in the US and suspension in the EU for its previous type 2 diabetes product Avandia (rosiglitazone)

More from news
Approximately 2 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This has been a consequence of the safety concerns over GlaxoSmithKline's Avandia (rosiglitazone) and the subsequent restrictions, which were then lifted in the US after further analysis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics